• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

Citing Suspected Vaccine Patent Infringement, GSK Files Lawsuit Against Pfizer


Company is seeking monetary damages from the alleged violation.

RSV vaccine vial with syringe - Respiratory syncytial virus shot. Image Credit: Adobe Stock Images/MargJohnsonVA

Image Credit: Adobe Stock Images/MargJohnsonVA

Believing the multinational company violated four patents relating to the use of Antigens in Arexvy, GSK has announced the filing of a lawsuit against Pfizer. According to the documents filed in court, Pfizer’s respiratory syncytial virus (RSV) vaccine, Abrysvo, was created with GSK’s “claimed inventions”. With GSK seeking monetary damages such as lost profits, Pfizer has denied any infringement, planning to defend its work.

As both Arexvy and Abrysvo have already received FDA approval, doses are now available to the public for use in adults over 60. As a part of legal proceedings, GSK has requested authorities to prevent Pfizer from selling its product.

Reference: GSK Sues Pfizer for Alleged RSV Vaccine Patent Infringement. BioSpace. August 2, 2023. Accessed August 3, 2023. https://www.biospace.com/article/gsk-sues-pfizer-for-alleged-rsv-vaccine-patent-infringement/?s=89

Related Videos
Related Content